Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Update

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 108,354 shares, an increase of 265.5% from the May 31st total of 29,643 shares. Based on an average daily volume of 327,763 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Zhengye Biotechnology Stock Performance

ZYBT stock opened at $0.71 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 1.14. The stock’s 50 day moving average is $0.88 and its 200-day moving average is $1.03. Zhengye Biotechnology has a twelve month low of $0.68 and a twelve month high of $13.08.

Zhengye Biotechnology (NASDAQ:ZYBT) last announced its earnings results on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $3.97 million for the quarter.

Institutional Trading of Zhengye Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of ZYBT. Citadel Advisors LLC purchased a new position in shares of Zhengye Biotechnology during the third quarter worth about $31,000. WINTON GROUP Ltd lifted its position in Zhengye Biotechnology by 193.8% during the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock valued at $73,000 after purchasing an additional 41,750 shares during the last quarter. Jane Street Group LLC bought a new stake in Zhengye Biotechnology during the second quarter valued at approximately $1,158,000. Invesco Ltd. bought a new position in shares of Zhengye Biotechnology in the 2nd quarter worth $220,000. Finally, Geode Capital Management LLC bought a new position in shares of Zhengye Biotechnology in the 2nd quarter worth $174,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.